Clinical Trials Logo

Clinical Trial Summary

Novel approaches to promote adherence to diabetic footwear and prevent high incidence of diabetes foot ulcers are urgently needed. Investigators propose to translate an innovative and practical technology to supplement clinical and risk evaluation for patients with diabetes through wearable insoles and smart watch, along with foot self-care education, to improve adherence to prescribed footwear and reduce incidence of foot ulcers in those with diabetes and at risk for foot ulcers.


Clinical Trial Description

Uncontrolled diabetes is the cause of diabetes-related limb amputations. Diabetes-related amputations are huge problems, expensive to manage, and affect the quality of life. Diabetes foot ulcers (DFU) are foot-related injuries to the foot that are a direct result of neuropathy and peripheral artery diseases and have been identified as major risk factors for amputations. To prevent DFU, diabetes footwear is recommended, however, adherence is poor. Patients are not routinely adherent to the recommended diabetic footwear. In addition, current diabetic footwear is not effective in preventing most initial and recurrent DFUs. Although the causal mechanisms for DFU are multi-factorial, evidence exists that elevated plantar pressure contributes to the development of DFU, which is currently managed by devices ineffective in reducing pressure in certain areas of the foot. Foot care education by clinicians regarding adherence to prescribed footwear is not effective in reducing the initial and recurrent DFUs. A recent study by Najafi and colleagues demonstrated the efficacy and feasibility of smart insoles with real-time alerts for plantar pressure offloading, which causes more than 50% of pressure ulcers in at-risk individuals with diabetes. The device was designed to cue offloading to manage unprotected sustained plantar pressures to prevent foot ulceration. Interestingly, their study suggested that in the group with at least 1 alert every 2 hours, adherence to prescribed footwear was increased or retained over time; whereas a lower number of alerts reduced adherence. Authors speculated that reduced adherence in the low-alert group may be linked to disengagement or reduced perception of benefit. It is unknown whether smart insoles with alerts will improve the use of footwear and lower the incidence of DFU, compared to usual care and the role of self-efficacy in mediating among performance, desired behavior, and desired outcomes (increase adherence to diabetic footwear and decrease the incidence of foot ulcer) among participants in the proposed study. To fill the gaps, investigators aim to examine whether integration of a diabetes foot self-care education and smart insoles with alerts may sustain adherence, irrespective of several daily alerts, to prescribed footwear, compared to usual care in those at risk for DFU. In this study (R21) phase, investigators are proposing a randomized controlled trial to evaluate the efficacy of insoles with real-time alert and foot self-care education in improving adherence to prescribed footwear in diabetes patients at risk for DFU. In Aim 1, investigators will examine whether smart insoles with real-time alert components plus foot self-care education compared to the smart insole with alerts alone and usual care will improve adherence to prescribed footwear in high-risk individuals for DFU (history of neuropathy and peripheral artery disease [PAD]). In Aim 2, investigators will examine trends across groups in the incidence of initial and recurrent DFU. The overall goal is to generate data for an R01 submission to evaluate the effectiveness of combined smart insoles with real-time alert plus foot self-care education in preventing the incidence of initial and recurrent DFU in those at-risk individuals with diabetes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05074849
Study type Interventional
Source Texas Woman's University
Contact Ngozi Mbue, PhD
Phone 7137942892
Email nmbue@twu.edu
Status Not yet recruiting
Phase N/A
Start date October 20, 2024
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03022721 - Heidelberg Study on Diabetes and Complications N/A
Withdrawn NCT02580266 - Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
Completed NCT02423434 - Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
Completed NCT03426566 - Abnormal Plantar Pressure in Patients With Diabetes
Completed NCT01695278 - A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community Phase 3
Completed NCT02588898 - B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes
Completed NCT00815178 - Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness N/A
Not yet recruiting NCT04537676 - Patient Empowerment Study
Terminated NCT02915263 - The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Phase 2
Completed NCT01929018 - Collaborative-care Rehabilitation After Dysvascular Amputation N/A
Completed NCT03877523 - Cocarnit Effects on Macrophages Polarization N/A
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Completed NCT02928939 - Therapeutic Conflicts and Multimorbidity
Recruiting NCT02275091 - Children With Diabetes at Risk for Heart Disease.
Terminated NCT00529204 - Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease Phase 2
Completed NCT04963998 - Safety and Efficacy Study of MedCu Wound Dressings N/A
Recruiting NCT06321029 - Electronic Diabetes Tune-Up Group (eDTU) for African Americans N/A
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Completed NCT05231642 - Individualised Postprandial Glucose Responses in Type 1 Diabetes N/A
Completed NCT03392441 - Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes N/A